Teacrina
Focus & Nootropics

Teacrina

Theacrine (1,3,7,9-tetramethyluric acid; often marketed as TeaCrine®) is an alkaloid structurally related to caffeine and theobromine. It is studied as a nootropic/focus aid to support alertness, motivation, and perception of fatigue, with some data suggesting lower development of tolerance compared with caffeine. The available clinical evidence is still limited and partly based on short-duration studies.

Purine alkaloid from Camellia and Kucha: focus, alertness, and mental fatigue with a profile distinct from caffeine

Theacrine

Theacrine (1,3,7,9-tetramethyluric acid; often marketed as TeaCrine®) is an alkaloid structurally related to caffeine and theobromine. It is studied as a nootropic/focus aid to support alertness, motivation, and perception of fatigue, with some data suggesting less tolerance development than caffeine. The available clinical evidence is still limited and partly based on short-duration studies.

Mechanism of action

Proposed mechanisms (not all definitively confirmed in humans): (1) modulation of the adenosinergic system (interaction with adenosine receptors, with effects on alertness and sleepiness); (2) dopaminergic modulation (hypothesized increase in dopaminergic tone/signaling, with possible effects on motivation and mood); (3) possible influence on neurotransmission and neuroinflammation in preclinical models. The structure-activity relationship compared with caffeine suggests partial overlap, but with potentially different pharmacokinetics and subjective profile.

Supported benefits

  • Increased alertness/attention and reduced perceived sleepiness in some contexts (limited)
  • Reduced perceived fatigue and support for subjective energy (limited)
  • Possible support for motivation/mood (subjective effects reported in some studies) (emerging)
  • Possible lower development of subjective tolerance compared with caffeine in the short term (emerging)

Safety & side effects

  • Insomnia or worsening sleep quality (more likely with afternoon/evening intake)
  • Nervousness, restlessness, anxiety (especially with co-use of caffeine or individual sensitivity)
  • Headache
  • Nausea or gastrointestinal disturbances
  • Palpitations or increased heart rate in sensitive individuals (limited clinical data; caution advised)

FAQ

Is theacrine the same as caffeine?

No. It is structurally related and may share some effects (alertness), but it has different pharmacokinetics (a longer reported half-life) and a subjective profile that in some studies appears less associated with short-term tolerance. Direct comparative evidence is still limited.

How long does the effect last?

Based on reported pharmacokinetics, the half-life may be on the order of many hours; this can translate into prolonged perceived effects and a greater risk of sleep interference if taken late.

Is it useful for athletic performance?

The data are preliminary. Some studies suggest possible benefits for energy/perceived fatigue, but the evidence for objective performance improvements is still limited and inconclusive.

Does it cause dependence or habituation?

There is no solid evidence of dependence. Some studies indicate less development of subjective tolerance compared with caffeine in the short term, but robust data on prolonged use and withdrawal symptoms are lacking.

Can it be combined with caffeine?

It has been studied in combination in some contexts and may increase alertness, but the additive stimulant effects may increase the risk of anxiety, palpitations, and insomnia. Assessment of individual risk is important.

The information provided is for informational and educational purposes only. It does not constitute medical advice. Use should be evaluated and authorized by a qualified healthcare professional.

Mechanism of action

Proposed mechanisms (not all definitively confirmed in humans): (1) modulation of the adenosinergic system (interaction with adenosine receptors, with effects on alertness and sleepiness); (2) dopaminergic modulation (hypothesized increase in dopaminergic tone/signaling, with possible effects on motivation and mood); (3) possible influence on neurotransmission and neuroinflammation in preclinical models. The structure-activity relationship relative to caffeine suggests partial overlap, but with potentially different pharmacokinetics and subjective profile.

Scientific benefits

Increased alertness/attention and reduced perceived sleepiness in some contexts
Evidence level: limited
Reduced perceived fatigue and support for subjective energy
Evidence level: limited
Possible support for motivation/mood (subjective effects reported in some studies)
Evidence level: emerging
Possible lower development of subjective tolerance compared with caffeine in the short term
Evidence level: emerging

Contraindications

  • Pregnancy and breastfeeding: avoid due to insufficient safety data
  • Pediatric/adolescent age: avoid due to insufficient data
  • Anxiety disorders, chronic insomnia, or high sensitivity to stimulants
  • Known cardiovascular conditions (arrhythmias, uncontrolled hypertension, heart disease): caution and professional evaluation
  • Significant liver or kidney disease: insufficient data, caution

Side effects

  • Insomnia or worsening sleep quality (more likely with afternoon/evening intake)
  • Nervousness, restlessness, anxiety (especially with co-use of caffeine or individual sensitivity)
  • Headache
  • Nausea or gastrointestinal disturbances
  • Palpitations or increased heart rate in sensitive individuals (limited clinical data; caution)

Interactions

  • Other stimulants (caffeine, guarana, yohimbine, synephrine, some pre-workouts): possible additive effects on the CNS and cardiovascular system
  • Drugs that affect sleep/anxiety (hypnotics, anxiolytics, some antidepressants): possible interference with sedation or anxious symptoms
  • Cardiovascular drugs (e.g. antiarrhythmics, antihypertensives): potential indirect interference through changes in heart rate/blood pressure in sensitive individuals
  • Substances metabolized by liver enzymes: specific data on enzymatic interaction of theacrine in humans are limited; caution with polypharmacy

Regulatory status

Marketed as an ingredient for dietary supplements in various markets; often present as a standardized extract (e.g. TeaCrine®). It is not typically listed among controlled substances, but rules on novel foods/ingredients and health claims vary by country. In sports, always check updates to anti-doping lists and the risk of contamination from multi-ingredient products.

Supplements and peptides

All supplements